LUX-Lung 7: is there enough data for a final conclusion? reply

被引：0
|
作者：
Park, Keunchil [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol,Innovat Canc Med Inst, Seoul 135710, South Korea
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 07期
关键词：
1ST-LINE TREATMENT; EGFR; INHIBITOR; AFATINIB;
D O I：
10.1016/S1470-2045(16)30244-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E268 / E269
页数：3
相关论文
共 50 条
  • [1] LUX-Lung 7: is there enough data for a final conclusion?
    Orlandi, Armando
    Calegari, Maria Alessandra
    Barone, Carlo
    LANCET ONCOLOGY, 2016, 17 (07): : E267 - E268
  • [2] Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
    Wu, Yi-Long
    Sequist, Lecia V.
    Tan, Eng-Huat
    Geater, Sarayut L.
    Orlov, Sergey
    Zhang, Li
    Lee, Ki Hyeong
    Tsai, Chun-Ming
    Kato, Terufumi
    Barrios, Carlos H.
    Schuler, Martin
    Hirsh, Vera
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Boyer, Michael
    Mok, Tony
    Peil, Barbara
    Marten, Angela
    Yang, James Chih-Hsin
    Paz-Ares, Luis
    Park, Keunchil
    CLINICAL LUNG CANCER, 2018, 19 (04) : E465 - E479
  • [3] Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo
    Schuler, M.
    Yang, J. C. -H.
    Planchard, D.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1172 - 1173
  • [4] Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    Yang, James C-H
    Sequist, Lecia V.
    Geater, Sarayut Lucien
    Tsai, Chun-Ming
    Mok, Tony Shu Kam
    Schuler, Martin
    Yamamoto, Nobuyuki
    Yu, Chong-Jen
    Ou, Sai-Hong I.
    Zhou, Caicun
    Massey, Daniel
    Zazulina, Victoria
    Wu, Yi-Long
    LANCET ONCOLOGY, 2015, 16 (07): : 830 - 838
  • [5] The aftermath of LUX-Lung 7 study-what have we learnt from it?
    Lee, Victor H. F.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (15)
  • [6] LUX-Lung trials—not all mutations are created equal
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2015, 12 (3) : 127 - 127
  • [7] What is the clinical impact of the LUX-Lung 5 trial?
    Addeo, A.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1171 - 1172
  • [8] LUX-Lung: determining the best EGFR inhibitor in NSCLC?
    Rossi, Antonio
    Di Maio, Massimo
    LANCET ONCOLOGY, 2015, 16 (02): : 118 - 119
  • [9] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
    Yang, James Chih-Hsin
    Wu, Yi-Long
    Schuler, Martin
    Sebastian, Martin
    Popat, Sanjay
    Yamamoto, Nobuyuki
    Zhou, Caicun
    Hu, Cheng-Ping
    O'Byrne, Kenneth
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Geater, Sarayut L.
    Lee, Kye Young
    Tsai, Chun-Ming
    Gorbunova, Vera
    Hirsh, Vera
    Bennouna, Jaafar
    Orlov, Sergey
    Mok, Tony
    Boyer, Michael
    Su, Wu-Chou
    Lee, Ki Hyeong
    Kato, Terufumi
    Massey, Dan
    Shahidi, Mehdi
    Zazulina, Victoria
    Sequist, Lecia V.
    LANCET ONCOLOGY, 2015, 16 (02): : 141 - 151
  • [10] The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
    Metro, Giulio
    Crino, Lucio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (05) : 673 - 682
12345